To identify genes influencing age at onset (AAO) in two common neurodegenerative diseases, a genomic screen was performed for AAO in families with Alzheimer disease (AD;
Introduction
Genetic studies of common complex neurodegenerative diseases, such as Alzheimer disease (AD [MIM 104300]) and Parkinson disease (PD [MIM 168600]), have focused on the identification of risk genes as targets for development of new treatments and improved diagnoses. This approach has identified the amyloid precursor protein (APP) (Goate et al. 1991) , presenilin 1 (PS1) , presenilin 2 (PS2) (Levy-Lahad et al. 1995; Rogaev et al. 1995) , and apolipoprotein E (APOE) (Corder et al. 1993 ) genes as contributing to risk in AD. APP, PS1, and PS2 cause rare early-onset autosomal dominant AD (5% of AD cases), whereas APOE is associated with both risk and age at onset (AAO) in late-onset familial AD, as well as in late-and early-onset sporadic AD. Similarly, three genes have been identified to associate with risk in PD: a-synuclein (Polymeropoulos et al. 1996) for rare autosomal dominant early-onset PD, Parkin (Abbas et al. 1999) for rare autosomal recessive juvenile parkinsonism and autosomal recessive early-onset PD, and tau (Martin et al. 2001) for classic PD. Genomic screens in both PD (Destefano et al. 2001; Scott et al. 2001 ) and AD (Kehoe et al. 1999; Pericak-Vance et al. 2000) have recently localized additional-but, as yet, unknown-risk genes.
However, risk is only one mode of genetic expression; AAO of disease may also be genetically influenced and may have an effect equivalent to that seen for the known risk genes (Daw et al. 2000) . Identification of such genes would open new avenues of research with the potential to delay onset beyond the natural life span. Present knowledge about genes contributing to AAO in neurodegenerative diseases clearly lags behind the understanding of genes contributing to risk. Recently, there has been growing interest in using AAO information as a quantitative trait, to identify genes that influence onset of disease (Daw et al. 1999 (Daw et al. , 2000 Duggirala et al. 1999) . Rapid development of methods of mapping quantitative trait loci (QTLs) for general pedigrees (Goldgar 1990; Amos 1994; Blangero and Almasy 1997) has now made the search for novel genes affecting AAO feasible. In this study, the variance-component procedure in SOLAR (Blangero and Almasy 1997 ) was used to perform genomewide scans on the quantitative trait AAO for AD and PD to map QTLs influencing AAO. This method is less penetrance-model dependent than the classical segregation/linkage-mapping technique, and it can take into account covariate or random effects. The common regions showing evidence of linkage from independent analyses of AD and PD data sets were analyzed further by use of the combined AD and PD data set. Because AD and PD share some common clinical and pathological findings, we hypothesized that a gene or genes common to both disorders control AAO and could be localized by use of this genomic-screening approach.
Material and Methods

Family Ascertainment
In this study, we used a total of 449 families affected with AD and 174 families affected with PD. Ascertainment of data from families with AD and PD was independently conducted by various research centers. The data from families with AD were ascertained by the following centers: the Duke Center for Human Genetics (CHG); the Joseph and Kathleen Bryan Alzheimer's Disease Research Center (Bryan ADRC); the Indiana Alzheimer's Disease Research Center National Cell Repository (IADRC); the National Institute of Mental Health (NIMH); and Vanderbilt University (VAN). In all data sets, affected individuals were classified in accordance with the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA) clinical diagnostic criteria (McKhann et al. 1984) . The reported AAO of patients with AD was defined as the age at which the caregiver, family, and/or individual first noted cognitive problems (most often short-term memory loss and, more rarely, other problems, such as dysphasia or disorientation to time or place, followed closely by memory change) sufficient to interfere with independent daily activities. The data from families with PD were ascertained by 13 centers in the United States and Australia (see Scott et al. 2001) . Diagnostic and exclusion criteria, based on previously published diagnostic criteria for PD (Ward and Gibb 1990; Hughes et al. 1992a Hughes et al. , 1992b , were adopted by all participating clinicians before beginning selection of families. Affected individuals were defined by having at least two cardinal signs of PD (e.g., rest tremor, bradykinesia, and rigidity) and no atypical clinical features or other causes of parkinsonism. The reported AAO was defined as the age at which an affected individual first noticed one of the cardinal signs of PD. In both AD and PD ascertainment, the reported AAE was recorded as the age at which study personnel clinically examined a participant. The data description is summarized in table 1. Overall, for AD, we have 1,121 affected individuals with reported AAO and 746 unaffected individuals with reported AAE, and, for PD, we have 378 affected individuals with reported AAO and 470 unaffected individuals with reported AAE. Average reported AAO ‫ע‬ SD was 72.8 ‫ע‬ 6.8 years for AD and 60.1 ‫ע‬ 12.7 years for PD. Average reported AAE for unaffected individuals was 70.2 ‫ע‬ 13.0 years for AD and 68.4 ‫ע‬ 12.7 years for PD. All participants or their legal representatives gave informed consent prior to joining the study, and data were collected according to protocols approved by each contributing group's institutional review board.
Modeling AAO Data
We modeled AAO data as described by Duggirala et al. (1999) , where AAO was suggested as a right-truncated quantitative trait in affected individuals (i.e., reported AAO is less than or equal to reported AAE) and a left-truncated quantitative trait in unaffected individ- NOTE.
-The polygenic models are: model 1, covariate at sex and affection status; and model 2, covariate at sex, affection status, and disease.
a The residual heritability is the ratio of the residual variance (after removing the covariate effects) to the total phenotypic variance. uals (i.e., reported AAO is greater than reported AAE). That is, the AAO data was comprised of reported AAO for affected individuals and reported AAE for unaffected individuals. Outliers and normality of the data were examined for agreement with the assumption of QTL analysis. Four outliers that were 4 SD below the mean AAO were excluded in the AD data set.
Linkage Analysis
We used the variance-components procedure in SO-LAR (Almasy and Blangero 1998) for linkage analysis. In theory, the quantitative phenotype AAO (y) was defined as a linear function of the n QTLs ( ) that influence r i the trait:
where X is a matrix of covariates and b is the regression coefficient matrix associated with the covariates. The phenotype is assumed to follow a normal distribution. The likelihood function of y includes the identical by descent (IBD) probability at a marker that is linked to a QTL, the additive genetic variance attributed by an unobserved QTL ( ), and other variance components. 2 j q SOLAR employs the likelihood-ratio test to test a null hypothesis of (no linkage) and generates a LOD 2 j p 0 q score that is the equivalent of the classical LOD score of linkage analysis. This technique can be applied to detect the evidence of linkage to an individual marker for two-point analysis or to an imputed chromosomal position in multipoint analysis. Locus-specific IBD information for pairs of relatives was obtained prior to computation of the likelihood function. The multipoint mapping strategy in SOLAR is an extension of the method of Fulker et al. (1995) . It requires the map distance between the markers to create the IBD information of a pair of relatives at a QTL that is linked to a marker. We used a Kosambi sex-averaged map obtained from Map-O-Mat (Lander and Green 1987; Matise and Gitlin 1999) . The linkage analysis method implemented in SO-LAR does not require specification of disease-allele frequency, penetrance, or mode of inheritance, which differs from the classical linkage mapping procedure. The initial genomic screens were performed on an AD data set of 449 families with a total of 4,316 relative pairs (sib pairs, cousin pairs, avuncular pairs, etc.) and a PD data set of 174 families with 2,256 relative pairs. A total of 323 (AD) and 330 (PD) microsatellite markers, with an average spacing of 10 cM, were analyzed (Vance and Ben Othmane 1998) . Since AAO was modeled as a truncated quantitative trait, the overall distribution of AAO was thus considered as a mixture of two truncated normal distributions. We included sex and affection status as covariates in the polygenic model (model 1), in which affection status was used for adjustment of the contribution of reported AAO and reported AAE to the quantitative trait AAO.
The common interesting (see below) regions identified by the initial linkage analyses of AD and PD data sets were followed up by use of the combined AD and PD (ADPD) data set for linkage analysis. There are many reasons to consider the hypothesis of similar genetic mechanisms leading to AAO in AD and PD. Both AD and PD are neurodegenerative, late-AAO disorders. Clinically, a significant number of patients with AD develop signs of parkinsonism, including bradykinesia, rigidity, and gait abnormalities (Wilson et al. 2000) . Conversely, dementia is a major factor in PD, and the two disorders both exhibit degeneration of cholinergic neurons in the nucleus basalis of Meynert (Korczyn 2001) . Another pathological similarity is the presence of similar staining a-synuclein Lewy bodies (LB) in both disorders, supporting the premise that the two diseases may share a common pathway leading to LB formation (Lippa et al. 2001) . APOE, a well-proven risk factor for AD, has been suggested, in some studies (e.g., Harhangi et al. 2000) , to be involved in the risk for PD as well, although others have failed to confirm these findings (Khan et al. 2001 ). In addition, frontotemporal dementia-17, caused by mutations in the tau gene, presents phenotypically with a dementia similar to AD coupled with parkinsonism (McKhann et al. 2001) . The tau gene, a major element in the neurofibulary tangles of AD, has recently been shown to be associated with PD as well (Martin et al. 2001) . These similarities are likely not derived from the biologic events that initiate the start of each disease but rather from overlapping neuropathic pathways involved in the progression of each disorder. It is these same pathways and modifier genes that are likely to contribute to phenotypic traits such as AAO, which is why we pooled these two neurodegenerative diseases for a combined analysis.
For the analysis of the ADPD data set, two polygenic models were considered, to incorporate two different scenarios:
Model 1.-We assumed that AD and PD are the same disease, so sex and affection status were included as covariates as that in the initial linkage analysis.
Model 2.-We considered that the distribution of the ADPD data set is a mixture of two normal distributions (AAO from AD and AAO from PD), so disease status was included as an additional covariate, to distinguish the different contribution of AAO between AD and PD.
Results
Polygenic Models Revealed Strong Heritability of AAO Genes
The analyses of polygenic models showed that sex, affection status, and disease were all significant covariates, for instance, with P values !.0001 for the ADPD data set. The proportion of variance contributed by all covariates included in the model ranged from 0.9% to 15.3% among different data sets (table 2). We found that the AD data set showed the smallest proportion of variance from all covariates (0.9%). This may be due to the larger sample size for AD than for PD or to the marginally significant effect of sex and affection status in AD ( for sex and for affection status). P p .03 P p .05 The heritability of AAO after these covariates were controlled for was highly significant in each of the data sets ( ), with heritabilities of 42% (AD), 62% (PD), P ! .0001 56% (ADPD, model 1), and 49% (ADPD, model 2) (table 2). These data strongly indicate that genes are important modulators of AAO.
Disease-Specific Linkage Evidence
The initial linkage analyses were performed on the AD and PD data sets separately. A threshold of LOD 11.00 was used for declaring a region "interesting" (table 3) (Weeks et al. 2000) and warranting follow-up analyses. Of greatest interest for PD is the result on chromosome 1, near D1S2134 (78 cM;
). For AD, ex-LOD p 3.41 amination of APOE, a known modulator of AAO in AD (Corder et al. 1993) , generated a LOD score of 3.28 in the AD data set, confirming its role as a modulator of AAO. In addition to APOE, strong AD-specific suggestive linkage regions on chromosome 4q at D4S1652 (208 cM;
) and chromosome 8q (150 cM, LOD p 2.29 LOD p ) were also found. Interestingly, neither chromosome 2.09 4q nor chromosome 8q have been reported as linkage regions with AD risk genes. It is possible that chromosomes 4q and 8q harbor genes that exclusively modulate onset of AD.
Linkage Evidence for a Common AAO Gene on Chromosome 10q
We found that, in the initial genomic screens, chromosomes 6 and 10 gave evidence for linkage to AAO in both the AD and PD data sets (table 3) . The peaks were 12 cM apart on chromosome 6 (51 cM in AD and 63 cM in PD) and were 7 cM apart on chromosome 10 (132 cM in PD and 139 cM in AD). To decipher the role of these common interesting linkage regions, we performed linkage analyses on the combined ADPD data set for chromosomes 6 and 10. Analysis of the ADPD data set by use of models 1 and 2 did not result in a consistent area of interest for chromosome 6, as the combined data set gave peak LOD scores of 1.96 at 154 cM for model 1 and 1.81 at 156 cM for model 2. This peak from the combined ADPD data set is unlinked to both the independent AD (51 cM) and PD (63 cM) regions. However, analysis of the ADPD data set on chromosome 10 confirmed the findings from the analyses of the independent AD and PD data sets, resulting in a single peak region on chromosome 10q between D10S1239 and D10S1237, with LOD scores of 2.33 for model 1 at 133 cM and 2.62 for model 2 at 135 cM (table 3) . Figure 1 summarizes the multipoint results of the four analyses on chromosome 10. As can be seen, four analyses revealed a similar pattern of LOD scores across chromosome 10, with a single peak region. Notably, inclusion of disease status as a covariate in model 2 slightly increases the LOD score in the ADPD data set. Our results strongly suggest that a common modulator of AAO for AD and PD may be located on chromosome 10q.
Discussion
Genomic screens have concentrated historically on identifying genes controlling the risk of developing a disease. However, risk is not the only important aspect of a disease. Onset of disease is also crucial, as understanding the regulation of onset could make it possible to delay onset beyond an individual's normal life span. The results of this study, the first genomic screens for AAO in two major neurodegenerative diseases (AD and PD), demonstrate that AAO is highly heritable and that the search for AAO genes is possible. It should be noted that AAO data are very difficult to acquire reliably, and falsenegative results may be produced. With this point in mind, this study followed published standards in ascertainment for definition of reported AAO for affected individuals and reported AAE for a participant. In ad- dition, the large sample sizes assembled for both AD and PD should help to decrease the false-negative outcome. Although some limitations may exist, overall, we believe that our data set has significant power to detect genes modulating AAO.
Elsewhere, Daw et al. (2000) reported that at least four AAO genes with effect size possibly equal to or greater than that of APOE exist. However, the chromosomal locations linked to these putative AAO genes are still unknown. The present genomic screen for AAO in AD has identified six suggested linkage regions for AAO, in which chromosomes 4q, 8q, and 10q show the most promising results, with LOD scores 12. The APOE gene still yielded the strongest linkage effect among the newly identified regions in AD, and the role of APOE in controlling onset of AD was further confirmed. For PD, we identified a single peak with very strong linkage evidence ( ) near D1S2134 LOD p 3.41 (78 cM). Previously, Valente et al. (2001) and van Duijn et al. (2001) had localized genes for rare autosomal recessive early-onset PD to two independent regions on chromosome 1p (PARK6 and PARK7, respectively). The minimal candidate region (MCR) for PARK6 defined by the observed recombination in the family is between D1S483 (45.3 cM) and D1S247 (57.8 cM), whereas the MCR for PARK7 is between D1S468 (4.2 cM) and D1S214 (14 cM). In addition, the weak support for linkage on chromosome 1q ( at 214 cM) LOD p 1.20 to PD risk reported by DeStefano et al. (2001) is unlinked to our region.
Several recent reports have focused attention on chromosome 10q for AD (Bertram et al. 2000; Ertekin-Taner et al. 2000; Myers et al. 2000; Haines and Pericak-Vance 2001) but have been inconsistent in localization ( fig. 2) . Only the region identified by Bertram et al. (2000) by use of the NIMH family-sample data set maps near our region. To clarify our results, we further tested two subsets of data: a subset of the AD data, made up of all the NIMH families (∼60% of the overall AD data set), and a combined ADPD data set, without NIMH data, for chromosome 10. First, the NIMH AD subset generated a LOD score of 1.00 near D10S677, which is adjacent to D10S1239 (6 cM apart). The remaining non-NIMH data set thus contributed equally to the overall LOD score in AD. Second, the combined ADPD data set without NIMH data generated LOD scores of 1.48 for model 1 and 1.55 for model 2, at D10S1239 (132 cM). Figure 2 depicts the map positions of published linkage regions for risk genes on chromosome 10q and our linkage findings for AAO genes. It is clear that the linkage effect on chromosome 10q spans the different data sets used in the analyses. Three independent risk-gene studies (ErtekinTaner et al. 2000; Myers et al. 2000; Haines and Pericak-Vance 2001) identified an overlapping region (between D10S1225 and D10S1211) that is ∼47 cM proximal to our linkage region for AAO. Only NIMH data showed an overlapping linkage region for both risk and AAO genes. Our findings suggest three possible explanations for the previously reported inconsistent localizations of risk genes on chromosome 10 (Myers et al. 2000) : (1) the same gene may affect both risk and onset in a subset of families, (2) onset and risk may be affected by separate genes within this region, or (3) the statistical methods may be detecting the genetic effects on onset when studying risk. Until the results can be replicated in different data sets, it is difficult to draw a conclusion at this stage to explain the inconsistent localization reported on chromosome 10. In addition, potential differences across ascertainment centers were investigated in our analysis by treating center as a random effect in the analyses. The center effect was not significant in PD but was significant in AD, with 1.9% heritability. After including the center effect for the AD data, the same peak region (near D10S1237) was found, with LOD p 2.03. These results confirmed that ascertainment through multiple centers is unlikely to significantly bias our findings on chromosome 10. For PD, no risk genes have yet been reported on chromosome 10 ). Our study is the first to link chromosome 10q to PD.
AD and PD, although distinct clinical entities, share some common clinical and pathological features. Both have substantial variability in AAO. Although Lewy bodies are a cardinal feature of PD (Lippa et al. 2001) , they can be found in individuals with autopsy-confirmed AD Scott et al. 2000) . Dementia is the primary feature of AD, but a substantial number of patients with PD also develop dementia as their PD progresses . Thus, it is possible that AD and PD share common etiologic pathways. The use of combined AD and PD data sets for linkage analysis is therefore justified. The results presented here point to one or more genes on chromosome 10 as a common modulator of AAO in these neurodegenerative diseases. 
